To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

CSF in Alzheimer's Diseas… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

CSF in Alzheimer's Disease

Review article
Authors Henrik Zetterberg
Ronald Lautner
Tobias Skillbäck
Christoffer Rosén
Pashtun Shahim
Niklas Mattsson
Kaj Blennow
Published in Advances in Clinical Chemistry
Volume 65
Pages 143-172
ISSN 0065-2423
Publisher Elsevier Academic Press Inc
Place of publication San Diego
Publication year 2014
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 143-172
Language en
Subject categories Neurosciences


Alzheimer's disease (AD) is a progressive brain amyloidosis that injures brain regions involved in memory consolidation and other cognitive functions. Neuropathologically, the disease is characterized by accumulation of a 42-amino acid protein called amyloid beta, and N-terminally truncated fragments thereof, in extracellular senile plaques together with intraneuronal inclusions of hyperphosphorylated tau protein in neurofibrillary tangles, and neuronal and axonal degeneration and loss. Clinical chemistry tests for these pathologies have been developed for use on cerebrospinal fluid samples. Here, we review what these markers have taught us on the disease process in AD and how they can be implemented in routine clinical chemistry. We also provide an update on new marker development and ongoing analytical standardization effort.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?